Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 204 от 240

Активно (без набиране) Фаза 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity Overweight Type 2 Diabetes

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).

Начало: 15.05.2025 Край: 01.08.2027 Възраст: от 18 г.

Argentina, China, Czechia +4 Eli Lilly and Company NCT06993792

Активно (без набиране) Фаза 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity Overweight

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.

Начало: 15.05.2025 Край: 01.08.2027 Възраст: от 18 г.

Argentina, China, Czechia +4 Eli Lilly and Company NCT06972459

Активно (без набиране)

Efficacy of Chlorhexidine and Morus Nigra Mouthwashes After Periodontal Treatment

Periodontitis Periodontal Disease

This study aims to evaluate and compare the clinical, biochemical, and microbiological effects of chlorhexidine and Morus nigra (blackberry) mouthwashes used as an adjunct to non-surgical periodontal treatment (scaling and root planing - SRP) in patients with periodontal diseases. The participants will be divided into three groups: a control group receiving only SRP, a group receiving SRP combined with chlorhexidine mouthwash, and a group receiving SRP combined with Morus nigra mouthwash. Clinical periodontal parameters, gingival crevicular fluid levels of inflammatory markers (including TNF-a, IL-1b, and IL-10), and subgingival plaque microbiological profiles (such as red complex bacteria and Fusobacterium) will be evaluated at baseline, 1 month, and 3 months after the treatment.

Начало: 08.05.2025 Край: 01.07.2026 Възраст: 18–65 г.

Turkey (Türkiye) Inonu University NCT07540624

Активно (без набиране) Фаза 3

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

Metastatic Malignant Neoplasm in the Bone Metastatic Malignant Solid Neoplasm

This phase III trial compares the effect of adding radiation therapy to usual treatment on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms, such as pain (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger). These bone metastases appear to be at higher risk of complications such as fracture, spinal cord compression, and/or pain warranting surgery or radiation treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. The total dose of radiation can be delivered in a single day or divided in smaller doses for up to 5 days of total treatment. Usual treatment for asymptomatic bone metastases may include drugs that prevent bone loss, in addition to the treatment for the primary cancer or observation (which means no treatment until symptoms appear). Evidence has shown that preventative radiation therapy may be effective in lowering the number of bone metastases-related complications, however, it is not known if this approach is superior to usual care. Adding radiation therapy to usual treatment may be more effective in preventing bone-related complications than usual care alone in cancer patients with asymptomatic high-risk bone metastases.

Начало: 07.05.2025 Край: 01.02.2029 Възраст: от 18 г.

Canada, United States NRG Oncology NCT06745024

Активно (без набиране) Фаза 1

A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults

Chronic Hepatitis b

The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of repeated administrations of AVX70371 in healthy participants.

Начало: 06.05.2025 Край: 31.08.2026 Възраст: 18–40 г.

Belgium AstriVax Therapeutics NCT06989788

Активно (без набиране)

Effects of Nada Yoga Music and Mandala Coloring During Labor on Pain, Anxiety, and Maternal Outcomes

Childbirth Labor Process

Aim: The aim of this study is to evaluate the effect of mandala coloring on labor pain, childbirth experience, and maternal satisfaction in pregnant women. Materials and Methods: This study is designed as an experimental study planned to be conducted between May 1, 2025 and May 1, 2026. The study population will consist of pregnant women admitted for live birth to the Obstetrics and Gynecology Department of Ağrı Training and Research Hospital during the study period. The sample size was determined based on a power analysis using an effect size of 0.80 (Cohen's d) obtained from a reference study, a significance level of 5% (α = 0.05), and a statistical power of 80% (1 - β = 0.80). According to the analysis conducted for four independent groups, it was determined that a total of 104 participants should be included in the study, with 26 participants in each group (mandala coloring group, Nada Yoga music group, mandala coloring + Nada Yoga music group, and control group).

Начало: 01.05.2025 Край: 30.04.2026 Възраст: от 18 г.

Turkey (Türkiye) Agri Ibrahim Cecen University NCT07533448

Активно (без набиране) Фаза 2

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease

The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.

Начало: 01.05.2025 Край: 01.05.2027 Възраст: от 16 г.

Belgium, Canada, France +4 Agios Pharmaceuticals, Inc. NCT06924970

Активно (без набиране)

Intervention Based on the Dietary Guidelines for the Brazilian Population for the Treatment of Overweight and Obesity

Obesity & Overweight Overweight (BMI > 25)

This clinical trial aims to evaluate how group-based food and nutrition education interventions, grounded in the recommendations of the Dietary Guidelines for the Brazilian Population, can improve participants' dietary quality and support the treatment of overweight and obesity. The study seeks to determine whether individuals with overweight and obesity receiving outpatient care who participate in collective food and nutrition education activities achieve benefits similar to those receiving individual nutritional counseling, particularly improvements in dietary intake, clinical parameters, and anthropometric measures. Participants will be divided into two groups and will be required to attend four monthly sessions, complete questionnaires before and after the sessions, and provide consent for the collection of data from their medical records. Researchers will compare the outcomes of participants attending group sessions with those receiving individual care to assess whether collective actions provide similar benefits in improving dietary quality, blood test results, and anthropometric measures.

Начало: 01.05.2025 Край: 01.12.2026 Възраст: от 18 г.

Brazil Federal University of Health Science of Porto Alegre NCT07538362

Активно (без набиране) Фаза 3

PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL

Acute T Lymphoblastic Leukemia (T-ALL)

This prospective multicenter study evaluates the efficacy and safety of PD-1 inhibitor combined with venetoclax and HAG/CAG chemotherapy in refractory/relapsed T-ALL (R/R T-ALL). Despite standard chemotherapy, R/R T-ALL remains challenging, with low salvage remission rates (\~40%) and poor survival. Preclinical data suggest PD-1 blockade enhances leukemic stem cell eradication, while venetoclax (BCL-2 inhibitor) synergizes with chemotherapy. Eligible patients receive 1-2 cycles of PD-1 inhibitor + venetoclax + CAG, with responders proceeding to allo-HSCT or MRD-guided consolidation. The trial aims to improve CR rates and survival, offering a novel immunochemotherapy approach for this high-risk population.

Начало: 01.05.2025 Край: 31.01.2029 Възраст: 18–70 г.

China Fujian Medical University Union Hospital NCT07541755

Активно (без набиране)

Outpatient VR (Virtual Reality)-Brain-gut Behavioral Therapies (BGBT) in Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Diseases

This research study is being done to learn if a virtual reality (VR)-directed BGBT program is feasible and acceptable for patients to enhance pain treatment for patients with IBD. The study hypothesis include: * the study will achieve greater than 75% program completion and 75% study assessment completion * patients with IBD will find VR-directed BGBT acceptable as an outpatient pain treatment * outpatient VR-directed BGBT in IBD arm participants will report a greater reduction in pain scores, symptom burden, stress, depression, anxiety, and pain-related interference and an improvement in health-related quality of life * will have lower opioid requirements and healthcare utilization at 4-weeks follow-up compared to the E-TAU arm

Начало: 29.04.2025 Край: 01.10.2027 Възраст: от 18 г.

United States University of Michigan NCT06910787

Активно (без набиране) Фаза 1

Psilocybin Brain Stimulation and Imaging Pilot Study

Healthy Volunteers

This open-label pilot psilocybin administration study investigates the influence of psilocybin on brain function and cognitive control functions in clinically and psychiatrically healthy volunteers. Participants will undergo experimental drug administration sessions after careful screening and preparation. Participants will also have brain activity measured using electroencephalogram (EEG) also during non-invasive brain stimulation using Transcranial Magnetic Stimulation (TMS).

Начало: 18.04.2025 Край: 01.08.2026 Възраст: 22–55 г.

United States Johns Hopkins University NCT06835699

Активно (без набиране)

Doula Model of Care

Perinatal Morbidity Mental Health

The goal of this randomized controlled intervention trial is to determine if an integrated partnership between a birth worker/community support organization and the Hospital of the University of Pennsylvania (HUP), will improve both the experience and outcomes for Black birthing people. The main question it aims to answer is whether an integrated partnership between a birth worker/community support organization and the Hospital of the University of Pennsylvania (HUP) will mitigate bias and mistrust thereby improving both the experience and outcomes for Black birthing people, assessed by the primary outcome of depression score. Participants will be randomized to Doula care (receive 2 prenatal visits, continuous intrapartum support, and 2 postpartum visits with a certified doula) or standard of care (receive prenatal care, labor and delivery, and postpartum care as they normally would if not in the study) and followed through 6 weeks postpartum.

Начало: 16.04.2025 Край: 01.11.2026 Възраст: 16–55 г.

United States University of Pennsylvania NCT06915259

Активно (без набиране)

Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis

Scleroderma

The purpose of this study is to examine whether an 8-week online educational group-based program tailored to people with systemic sclerosis can help improve cognitive function and well-being. The study team hypothesize that participants that receive the intervention will have better improvements immediately after treatment at week 8 in all cognitive function measures, non-cognitive symptoms, and self-management compared to those in the waitlist control.

Начало: 16.04.2025 Край: 01.12.2026 Възраст: 18–70 г.

United States University of Michigan NCT06880627

Активно (без набиране) Фаза 1

First-In-Human Study to Evaluate Single and Multiple Ascending Doses of JUV-161 in Healthy Adult Volunteers

Healthy Volunteer

The present First-In-Human (FIH) study (JUV-161-101) aims to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple subcutaneous (SC) doses of JUV-161 in healthy volunteers. The study design is well-established for FIH studies and appropriate to assess the preliminary safety and tolerability of new drug candidates. Data from this study will support conduct studies in patients with DM1 as well as supporting studies in other degenerative myopathies and other disorders for which preclinical efficacy data have been obtained.JUV-161 has not been previously been administered to human subjects.

Начало: 14.04.2025 Край: 30.06.2026 Възраст: 18–60 г. Лечение

Australia Juvena Therapeutics NCT06918925

Активно (без набиране)

Pilot RCT and Interview Study on an HIV Chatbot in Nigeria

HIV

This study will investigate the use of a HIV chatbot that acts as an informational coach. The main question the study aims to answer is: Does the chatbot improve HIV knowledge in adults (older than 18-years) newly diagnosed with HIV in Nigeria - compared to a control group? Moreover, the study will also determine potential effects of the chatbot use on patients' resilience, psychological well-being. The study will explore patients' use and perceptions of the chatbot, as well as potential gender differences. The control group will receive Standard of Care only. Patients in the chatbot intervention group will interact with the chatbot in addition to receiving Standard of Care. They will be able to: * Use a chatbot via WhatsApp * Receive information on relevant HIV topics * Get automated responses to their HIV-related questions * Be reminded of medical appointments and medication schedules

Начало: 14.04.2025 Край: 20.06.2026 Възраст: от 18 г.

Nigeria Christoph Pimmer NCT06814041

Активно (без набиране)

Open Pilot Trial of a Mind-Body Intervention for Patients With Chronic Hip Pain

Hip Pain Hip Pain Chronic Mind-Body Therapies

The goal of this study is to conduct a feasibility open pilot study (N=5) of HIPS with virtual exit interviews among adult patients with chronic hip joint-related pain (HRP). We will use this mixed methods information to assess the feasibility, credibility, and acceptability of the HIPS intervention and optimize the program and study methodology in preparation for a pilot feasibility randomized control trial (RCT). Deliverables: \[1\] Adapt and refine open pilot protocol, patient recruitment, provider training, and other study materials. \[2\] Assess the feasibility, acceptability, and credibility of HIPS in preparation for a future feasibility RCT.

Начало: 04.04.2025 Край: 01.09.2026 Възраст: от 18 г.

United States Massachusetts General Hospital NCT06820242

Активно (без набиране) Фаза 2

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Obesity Overweight or Obesity

This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.

Начало: 01.04.2025 Край: 01.10.2026 Възраст: 18–70 г.

United States Metsera, a wholly owned subsidiary of Pfizer NCT06973720

Активно (без набиране) Фаза 2

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Gastrointestinal Cancer

Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn if the cancer responds to treatment (gets smaller or goes away).

Начало: 01.04.2025 Край: 04.01.2029 Възраст: от 18 г.

Argentina, Canada, Chile +7 Merck Sharp & Dohme LLC NCT06864169

Активно (без набиране)

Testing a Digital Tool to Support Healthy Pregnancies

Preventive Behaviors Antenatal Care and Delivery

The delivery of preventive care for modifiable health risks (smoking, nutrition, alcohol, physical activity and gestational weight gain) is a critical part of antenatal care. Clinical guidelines recommend that preventive care is delivered using three elements: Ask, Advise, and Help (AAH). Unfortunately, the AAH model for modifiable risk factors is not routinely delivered to all pregnant people in face-to-face antenatal visits. The investigators will test if adding a digital support tool to usual antenatal care increases the provision of guideline-recommended preventive care for smoking, nutrition, alcohol, physical activity and gestational weight gain, compared to usual antenatal care at two maternity services based at Maitland Hospital and Manning Base Hospital in New South Wales, Australia. The digital support tool will provide the opportunity for pregnant people to self-assess smoking, nutrition, alcohol, physical activity and gestational weight gain risk prior to their antenatal visits, while also being provided with tailored guideline-based information and the opportunity to self-refer to support services. Use of the digital support tool may also prompt pregnant people and/or their antenatal clinicians to have discussions around smoking, nutrition, alcohol, physical activity and gestational weight gain risks at antenatal appointments. As well as assessing impact on receipt of care for smoking, nutrition, alcohol, physical activity and gestational weight gain, the investigators will also explore the feasibility, acceptability, barriers/enablers to use and content and functional preferences of the digital support tool for pregnant people.

Начало: 01.04.2025 Край: 01.05.2026 Възраст: от 18 г. Превенция

Australia Hunter and New England Health NCT06896292

Активно (без набиране)

The Influence of Genetic Polymorphism on Dose- Dependent Analgesic Response and Safety to Propofol in General Anesthesia

Analgesia

This study investigates the influence of genetic polymorphisms in key drug-metabolizing enzymes-CYP2B6, CYP2C9, and UGT1A9-on the individual response to propofol, a widely used intravenous anesthetic, in patients undergoing general anesthesia. Despite propofol's fast onset and favorable recovery profile, significant inter-individual variability exists in its dosing requirements, sedation depth, and adverse effects. Such variability is believed to arise in part from genetic differences that affect drug metabolism and action. This research focuses on identifying how specific gene variants, particularly those linked to poor or altered metabolizer phenotypes, influence clinical outcomes like induction time, recovery time, and safety profiles during anesthesia.

Начало: 01.04.2025 Край: 01.04.2027 Възраст: 18–60 г.

Pakistan Superior University NCT07543523

1 … 202 203 204 205 206 … 240